Similar articles for PMID: 30256438

Year	Number of Results
1998	1
1999	3
2000	4
2001	7
2002	6
2003	8
2004	1
2005	7
2006	6
2007	5
2008	9
2009	5
2010	1
2011	1
2012	6
2013	7
2014	2
2015	4
2016	7
2017	6
2018	6
2019	17
2020	7
2021	21
2022	12
2023	1
2024	0

1

MAPK/ERK pathway inhibition is a promising treatment target for adrenocortical tumors.

Pereira SS, Monteiro MP, Costa MM, Ferreira J, Alves MG, Oliveira PF, Jarak I, Pignatelli D. Pereira SS, et al. J Cell Biochem. 2019 Jan;120(1):894-906. doi: 10.1002/jcb.27451. Epub 2018 Sep 6. J Cell Biochem. 2019. PMID: 30256438

2

IGF2 role in adrenocortical carcinoma biology.

Pereira SS, Monteiro MP, Costa MM, Moreira Â, Alves MG, Oliveira PF, Jarak I, Pignatelli D. Pereira SS, et al. Endocrine. 2019 Nov;66(2):326-337. doi: 10.1007/s12020-019-02033-5. Epub 2019 Aug 4. Endocrine. 2019. PMID: 31378849 Free PMC article.

3

Resistance to mitogen-activated protein kinase kinase (MEK) inhibitors correlates with up-regulation of the MEK/extracellular signal-regulated kinase pathway in hepatocellular carcinoma cells.

Yip-Schneider MT, Klein PJ, Wentz SC, Zeni A, Menze A, Schmidt CM. Yip-Schneider MT, et al. J Pharmacol Exp Ther. 2009 Jun;329(3):1063-70. doi: 10.1124/jpet.108.147306. Epub 2009 Mar 3. J Pharmacol Exp Ther. 2009. PMID: 19258520

4

Efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in a preclinical model of adrenocortical carcinoma.

Doghman M, Lalli E. Doghman M, et al. Mol Cell Endocrinol. 2012 Nov 25;364(1-2):101-4. doi: 10.1016/j.mce.2012.08.014. Epub 2012 Aug 31. Mol Cell Endocrinol. 2012. PMID: 22960230

5

GPER agonist G-1 decreases adrenocortical carcinoma (ACC) cell growth in vitro and in vivo.

Chimento A, Sirianni R, Casaburi I, Zolea F, Rizza P, Avena P, Malivindi R, De Luca A, Campana C, Martire E, Domanico F, Fallo F, Carpinelli G, Cerquetti L, Amendola D, Stigliano A, Pezzi V. Chimento A, et al. Oncotarget. 2015 Aug 7;6(22):19190-203. doi: 10.18632/oncotarget.4241. Oncotarget. 2015. PMID: 26131713 Free PMC article.

6

Importance of MEK-1/-2 signaling in monocytic and granulocytic differentiation of myeloid cell lines.

Miranda MB, McGuire TF, Johnson DE. Miranda MB, et al. Leukemia. 2002 Apr;16(4):683-92. doi: 10.1038/sj.leu.2402400. Leukemia. 2002. PMID: 11960350

7

Livin/BIRC7 expression as malignancy marker in adrenocortical tumors.

Altieri B, Sbiera S, Della Casa S, Weigand I, Wild V, Steinhauer S, Fadda G, Kocot A, Bekteshi M, Mambretti EM, Rosenwald A, Pontecorvi A, Fassnacht M, Ronchi CL. Altieri B, et al. Oncotarget. 2017 Feb 7;8(6):9323-9338. doi: 10.18632/oncotarget.14067. Oncotarget. 2017. PMID: 28030838 Free PMC article.

8

Thapsigargin induces apoptosis in adrenocortical carcinoma by activating endoplasmic reticulum stress and the JNK signaling pathway: an in vitro and in vivo study.

Wu L, Huang X, Kuang Y, Xing Z, Deng X, Luo Z. Wu L, et al. Drug Des Devel Ther. 2019 Aug 12;13:2787-2798. doi: 10.2147/DDDT.S209947. eCollection 2019. Drug Des Devel Ther. 2019. PMID: 31496655 Free PMC article.

9

MEK/ERK-mediated proliferation is negatively regulated by P38 map kinase in the human pancreatic cancer cell line, PANC-1.

Ding XZ, Adrian TE. Ding XZ, et al. Biochem Biophys Res Commun. 2001 Mar 30;282(2):447-53. doi: 10.1006/bbrc.2001.4595. Biochem Biophys Res Commun. 2001. PMID: 11401480

10

Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells.

Vintman L, Nielsen S, Berner A, Reich R, Davidson B. Vintman L, et al. Cancer. 2005 Jun 1;103(11):2427-33. doi: 10.1002/cncr.21014. Cancer. 2005. PMID: 15830375 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

149 results

Results by year